Zantac

Stalemate in Zantac Cancer Trial, No Sanctions in Talc Case, and Visa Faces Antitrust Allegations

by

Oakland, Calif. — A high-profile trial in California questioning the safety of the heartburn medication Zantac concluded ambiguously when jurors could not reach a unanimous decision, leading to a mistrial. The trial, marked by intense deliberations, was held at the Alameda County Superior Court, where the jurors split 6-6 on a critical lawsuit allegation against the pharmaceutical company Boehringer Ingelheim. The jurors agreed on the initial five items of the lawsuit but deadlocked on the sixth, which questioned whether Boehringer’s failure to provide adequate warnings about the drug’s potential cancer risks was a substantial factor … Read more

Pharmaceutical Giants Seek Delaware Supreme Court Intervention Over Expert Testimony in Zantac Case

by

Dover, Delaware — In a significant legal development, major pharmaceutical companies have escalated a Delaware-based litigation concerning the popular heartburn medication Zantac. GlaxoSmithKline, Pfizer, Sanofi, and Boehringer Ingelheim are challenging a ruling by the Delaware Superior Court that endorses the admissibility of expert testimony from the plaintiffs. Represented by top national law firms such as Dechert, Williams & Connolly, DLA Piper, and King & Spalding, these companies assert their concerns over the standards applied in the state’s court, suggesting a discrepancy with federal court standards. The companies took their grievances to the Delaware Supreme Court, … Read more

GSK Settles U.S. Zantac Cancer Claims for $2.2 Billion, Boosting Stock by 6%

by

London – GSK’s stock soared by 6% on Thursday following the announcement that the British pharmaceutical giant has agreed to a multi-billion dollar settlement over allegations that its now-discontinued heartburn medication, Zantac, was carcinogenic. The company will pay up to $2.2 billion to resolve almost all the pending lawsuits in the United States, which is significantly lower than some financial analysts had anticipated. Previously, forecasts by entities such as JP Morgan had estimated potential liabilities to be as high as $3.5 billion. However, the settlement disclosed on Wednesday accounts for about 80,000 cases—or 93%—of the … Read more

Delaware Supreme Court to Review Key Legal Challenges in Massive Zantac Cancer Case

by

Dover, Delaware — Home to more than two-thirds of Fortune 500 companies, Delaware is a beacon of corporate incorporation. The state’s reputation as a legal hub for business is now under the spotlight as the Delaware Supreme Court considers a pivotal appeal that could redefine its approach to mass-tort litigation. Delaware recently came to the forefront of legal discussions due to a substantial case involving over 75,000 plaintiffs. These individuals allege that ranitidine, often sold under the brand name Zantac, is carcinogenic. They argue that the drug breaks down into N-nitrosodimethylamine (NDMA), a substance believed … Read more